Isotechnika Pharma Inc IPHAF

RE: Roche

[biodelatech]

I don´t think it´s priced in. but arguing about fair valuations of small pharma companies with no products on the market is a waste of time. we all assume 247 will be approved for multiple indications. once we have the approvals,which I consider very likely, we´ll have to wait for the first sales figures. I expext 247 to be a blockbuster, more than 1 billion in sales. cyclosporin had more than 1 billion in peak sales, prior to generic competition. 247 is just an improved cyclosporin, hence it has that potential.